Regd. Office: Nirmala Apartment, 93, Jayprakash Road, Andheri (West), Mumbai - 400 058. Phone: 022-67 603 603 Fax: 91-22-66943127

Ref. No. : JPL/CS/1630/2020

Date : 2nd July, 2020.

*

CIN No. L24230MH1985PLC036541

To BSE Ltd., P J Towers, Dalal Street, Mumbai - 400 001.

Sub. : <u>Newspapers Publication of Audited Financial Results for the quarter and year</u> ended on 31 March, 2020.

Dear Sir,

Kindly find enclosed, cuttings of following two Newspapers dated 2nd July, 2020 containing the audited financial results of the Company for the quarter and year ended on 31st March, 2020.

The Free Press Journal, Mumbai (English) and
Navshakti, Mumbai (Marathi).

Kindly acknowledge.

Thanking you,

Yours faithfully, For Jenburkt Pharmaceuticals Ltd.,

- (Ashish R. Shah) Company Secretary.

Encl.: As stated above.

Science hai toh Hope hai 2 Hope hai toh Health hai 3 Health hai toh Happiness hai 3

www.jenburkt.com

*

*

मुंबई, गुरुवार, २ जुलै २०२

THE FREEPRESSOR	UKMAL
www.freepressjournal.in	MUMBAI THURSDAY JULY 2, 2020

TOTTON DODDO

JENBURKT

JENBURKT PHARMACEUTICALS LTD.

Regd. Office: Nirmala Apartments., 93, J. P. Road, Andheri (W), Mumbai-400 058 CIN: L24230MH1985PLC036541 + Tel:66943121 + Fax:66943127 + E-mail: investor@ienburkt.com

EXTRACT OF STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED ON 31/03/2020

1	m aregingin prito i d'he pelopeop severit 1.240	0 1	0.1	Questes	Year	Year
		Quarter	Quarter	Quarter	ended	ended
ir.	Particulars	ended	ended	ended	31.03.20	31.03.19
10.	Falticulais	31.03.20	31.12.19	31.03.19		
	and the second of the second of the	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
1.	Total Income from Operations (Net)	3156.46	3442.84	3605.83	12310.92	12605.40
	Net Profit / (Loss) for the period (before	688.92	667.20	. 939.22	2113.78	2663.34
3.	tax, Exceptional and Extra ordinary items) Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary	688.92	667.20	939.22	2113.78	2663.34
	items) Net Profit / (Loss) for the period after tax	461.65	463.88	689.45	1486.96	1979.78
	(after Exceptional and/or Extraordinary items) Total Comprehensive Income for the period (Comprising Profit / (Loss) for the period after tax) and other Comprehensive	200.20	489.31	665.57	1253.57	1952.49
j.	Income (after tax) Paid-up Equity Share Capital	458.94	458.94	458.94	458.94	458.94
	(F.V. of Rs.10/- each) Reserves and surplus (excluding		FI Fals	-	7541.49	7287.6
	revaluation reserve) Earnings per share (EPS) (F.V. of Rs.10/- each) (for continuing& discontinued operations)	10.06	10.11	15.02	32.40	43.14

NOTES:

1. The above is an extract of the detailed format of Audited Financial Results for the quarter & financial year ended on 31st March, 2020 filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results for the Quarter and Financial Year ended on 31st March, 2020 are available on the website of the Stock Exchange viz. www.bseindia.com and that of the Company viz. www.jenburkt.com.

2. The figures of the previous period have been regrouped/rearranged to render them comparable with figures of the current period.

> By order of the Board For JENBURKT PHARMACEUTICALS LTD.

15

(Ashish U. Bhuta) Chairman & Managing Director

JENBURKT

JENBURKT PHARMACEUTICALS LTD.

Regd. Office: Nirmala Apartments., 93, J. P. Road, Andheri (W), Mumbai-400 058 CIN: L24230MH1985PLC036541 + Tel:66943121 + Fax:66943127 + E-mail: investor@jenburkt.com

EXTRACT OF STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED ON 31/03/2020

1. 5000		(Rs. In Lacs except EPS)						
Sr. No.	Particulars	Quarter ended 31.03.20	Quarter ended 31,12,19	Quarter ended 31.03.19	Year ended 31.03.20	Year ended 31.03.19		
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)		
1.	Total Income from Operations (Net)	3156.46	3442.84	3605.83	12310.92	12605.40		
2.	Net Profit / (Loss) for the period (before tax, Exceptional and Extra ordinary items)	688.92	667.20	939.22	2113.78	2663.34		
3.		688.92	667.20	939.22	2113.78	2663.34		
4.	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	461.65	463.88	689.45	1486.96	1979.78		
5.		200.20	489.31	665.57	1253.57	1952.49		
6.	Paid-up Equity Share Capital (F.V. of Rs.10/- each)	458.94	458.94	458.94	458.94	458.94		
7.	Reserves and surplus (excluding revaluation reserve)	1	-	- 14	7541.49	7287.61		
8.	Earnings per share (EPS) (F.V. of Rs.10/- each) (for continuing& discontinued operations) (Basic & Diluted)	10.06	10.11	15.02	32.40	43.14		

NOTES:

1. The above is an extract of the detailed format of Audited Financial Results for the guarter & financial year ended on 31st March, 2020 filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results for the Quarter and Financial Year ended on 31st March, 2020 are available on the website of the Stock Exchange viz. www.bseindia.com and that of the Company viz. www.jenburkt.com.

2. The figures of the previous period have been regrouped/rearranged to render them comparable with figures of the current period.

> By order of the Board For JENBURKT PHARMACEUTICALS LTD.

Place: Mumbai Date: 30/6/2020

(Ashish U. Bhuta) Chairman & Managing Director

Place: Mumbai Date: 30/6/2020